Despite urgent medical need, a broadly effective antiviral therapy for the treatment of infections with hepatitis C viruses has yet to be developed. One of the approaches to anti-hepatitis C virus drug discovery is the development and design of specific small molecule drugs to inhibit the proteolytic processing of the polyprotein. This review will focus on recent developments in our understanding of the structure and function of the hepatitis C virus NS3/4A serine protease.